UPDATE! US Stem Cell Inc (OTCMKTS:USRM) Plunges on Open


US Stem Cell UPDATE!

Shares plunged on the open by around 35% after news was released by the company that it would not pursue a Regenerative Medicine Advanced Therapy FDA designation at this time. Instead, US Stem Cell will allocate resources towards expanding their existing 12 stem cell clinics and treatment centers. Volumes are heavy!

US Stem Cell Inc (OTCMKTS:USRM) released positive quarterly earnings in early May and has now announced more positive news in the form of global recognition for the efforts of its Chief Science Officer Kristin Comella.

US Stem cell, Inc. is a promising company in the stem cell industry. They focus on regenerative medicine and cellular therapy. US Stem Cell Inc (OTCMKTS:USRM) discovers, develops, and commercializes cell-based treatments that addresses disease by repairing and/or replacing damaged cell tissue, cells, and organs. US Stem Cell Inc (OTCMKTS:USRM) has three operating divisions – US Stem Cell Training, Vetbiologics, and the US Stem Cell Clinic. These divisions monetize their efforts by developing proprietary cell therapy products and training for healthcare professionals.

In 2016, the size of the global stem cell industry was estimated to be in excess of $68.7 billion. However, the market’s growth is being restricted by the high cost of treatment compounded by a lack of reimbursement policies by insurance carriers. Also contributing to growth impairment is burdensome government regulation in response to the unethical harvesting of stem cells.

US Stem Cell Inc (OTCMKTS:USRM) stock has suffered over the past few years. In 2014 USRM shares were briefly trading over $50 but today the shares can be had for under $0.10 – ten cents. Obviously there has been a lack of execution and ability to generate profits. However it appears what they do not lack is intellectual capacity. A scientific paper regarding intramyocardial implantation, co-authored by Kristin Comella, Chief Science Officer of US Stem Cell Inc (OTCMKTS:USRM), has been recognized as one of the most influential papers of 2016 according to This is not the first time that Kristin Comella has been recognized for her contributions to stem cell science. She was also named #24 on Terrapin’s list of top 50 Global Stem Cell Influencers. She was also listed at #1 on the Academy of Regenerative Practices list of Top Ten Stem Cell Innovators. Mr. Comella also led the team that achieved the first ever FDA approval for a clinical trial for a heart product that used a combination of cell and gene therapies.

Here is a link to the paper highlighted above –

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $USRM and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc Anderson is a pseudonym. Marc has a degree in economics and a MSc. in Finance. Marc worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

US Stem Cell Inc. (OTCMKTS:USRM)

Renewed Interest In US Stem Cell Inc. (OTCMKTS:USRM) After Stellar Q1 And $5 Million Private Investment

Investors Renew Interest On US Stem Cell Inc. (OTCMKTS:USRM)

US Stem Cell Inc. (OTCMKTS:USRM) stock continues to experience increased volatility in the market as the stock rallied by more than 20% in Thursday’s trading session. Renewed investor interest comes on the heels of the company reporting positive first quarter results after General American Capital bet big on the company’s growth prospects with a $5 million investment.

Stellar Q1 Results

The leader in regenerative medicine and cellular therapy generated revenues of $1.15 million for the first three months of the year. First quarter revenues represented a 62% increase from $710,000 reported for the same quarter last year. Gross profit in the quarter was also up by 45.6%, soaring to $810,000 from the $556,000 reported for the same period last year.

US Stem Cell Inc. (OTCMKTS:USRM) ended the first quarter cash positive, having seen its cash balance soar to $268,000 from $62,000 as of Q1 2016. Buoyed by the first quarter results, the company’s chief executive officer, Mike Tomas, has reiterated commitment to pursuing strategic business initiatives geared towards growing top line revenues.

General American Partners Big Bet

Impressed by the growth prospects of US Stem Cell Inc. (OTCMKTS:USRM), General American Partners reiterated its commitment to invest up to $5 million in exchange for 63, 873,275 shares of USRM. The private equity firm remains confident of the company’s long-term prospects driven by the growing demand for regenerative medicine procedures.

“We see exponential growth in the stem cell industry, estimated to grow to $170 billion by 2020. We are very pleased to join forces with U.S. Stem Cell, Inc., a leader in regenerative medicine solutions, to help expand our role in this important market,” said Joseph DaGrosa, Jr., a Principal of General American Partners.

The developer of stem cell therapies has applied for a Regenerative Advanced Therapy designation from the FDA for its MyoCell product. The regenerative product has already demonstrated clinical efficacy in clinical trials, a milestone that US Stem Cell remains confident will be key to it gaining RAT designation as a novel treatment for life-threatening diseases.

US Stem Cell Inc. (OTCMKTS:USRM) stock was a big mover in Thursday’s trading session having rallied by 26.67% in the day to close at $0.104 a share. The stock is currently trading in the $0.08-$0.10 trading range and close to its 52-week high of $0.18 a share.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $USRM and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica Gray has an undergraduate degree in Accounting and an MBA – earned with Honors. She has six years of experience in the financial markets and has been a securities analyst for the past two years.

US Stem Cell Inc (OTCMKTS:USRM) Receives Institutional Fund Injection


US Stem Cell Inc (OTCMKTS:USRM) is a biotechnology company that was formerly known as Bioheart, Inc. US Stem Cell, headquartered in Sunrise, FL, seeks to discover, develop, and commercialize autologous cell therapies for the treatment of chronic and acute heart damage. The company’s current drug candidates include MyoCell, MyoCell SDF-1, and AdipoCell. On April 13, 2017 US Stem Cell Inc (OTCMKTS:USRM) announced that it had received a commitment to invest up to $5,000,000 from private equity firm General American Capital Partners LLC (GACP) in exchange for up to 63,873,275 shares of common stock.

MyoCell is being developed by US Stem Cell Inc (OTCMKTS:USRM) as a treatment to improve cardiac function months or years after a patient has experienced heart damage due to a heart attack. The treatment involves the removal of a small amount of muscle from the patient’s thigh. Muscle stem cells, called myoblasts, are isolated and expanded utilizing a proprietary cell-culturing process. These cells are then injected directly into the heart’s scar tissue through an endoventricular needle-injection catheter by a surgeon. The stem cells then populate the area of scar tissue to, hopefully, improve cardiac function. The peer-reviewed American Heart Journal published the results of clinical trial Marvel-1. According to the article, when compared with a placebo, myoblast therapy was associated with sustained (six months) improvements in six-minute walk distance of >90 meters, a clinically meaningful improvement.

US Stem Cell Inc (OTCMKTS:USRM) is also developing MyoCell SDF-1. This treatment has recently received approval from the U.S Food and Drug Administration (FDA) to begin human clinical trials. MyoCell SDF-1 is being developed as an improvement to the MyoCell treatment. In preclinical studies, MyoCell SDF-1 provided a 54% improvement of heart function compared to 27% for the original MyoCell composition, while the placebo control treated animals declined by 10%. The preclinical studies also demonstrated that this product candidate can enhance blood vessel formation in damaged hearts.

Lastly, US Stem Cell Inc (OTCMKTS:USRM) is also developing its AdipoCell treatment. Adipose (fat) tissue is readily available and has been shown to be rich in microvascular, myogenic and angiogenic cells. In collaboration with the Regenerative Medicine Institute in Tijuana, Mexico, congestive heart failure patients are being treated in a Phase I/II trial at Hospital Angeles Tijuana. Reportedly, these patients have demonstrated, on average, an absolute improvement of 13% in ejection fraction and an increase of 100 meters in their six-minute walk distance. US Stem Cell Inc (OTCMKTS:USRM) has recently applied to the FDA to begin trials using adipose derived stem cells or AdipoCell™ in patients with chronic ischemic cardiomyopathy. The therapy involves the use of stem cells derived from the patient’s own fat (adipose tissue) obtained using liposuction. Transplantation of AdipoCell™ is accomplished through endocardial implantations with an injection catheter.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading.